Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
1999-12-28
2001-07-03
Geist, Gary (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S026400
Reexamination Certificate
active
06255294
ABSTRACT:
TECHNICAL FIELD
The invention relates to the use of nutritional supplements to treat disease. It relates particularly to treatment of IgE-type allergies, such as allergic rhinitis (hayfever) and allergic asthma, by the repeated administration over a period of time of vitamin B
12
, preferably cyanocobalamin, to reduce the symptoms associated with such allergic diseases.
BACKGROUND ART
The symptoms of allergic diseases, such as allergic rhinitis (hay fever) and allergic asthma, can be caused by a variety of atopic allergens, such as grasses, trees, weeds, animal dander, insects, molds, drugs and chemicals. These allergic diseases are mediated by an antibody known as immunoglobulin E, or simply IgE. Anti-IgE medicines that reduce IgE levels are attractive treatments for allergy patients.
IgE bonds to mast cells and basophils. Upon combination of a specific allergen with IgE bound to mast cells or basophils, the IgE may be crosslinked on the cell surface, resulting in the physiological effects of IgE-antigen interaction. This may result in the release of histamine, serotonin, heparin, a chemotactic factor for eosinoplylic leukocytes and/or the leukotrienes, C4, D4 and E4, which cause prolonged constriction of bronchial smooth muscle cells. These released substances are the mediators which result in allergic symptoms.
Vitamin B
12
is essential to cell growth, cell reproduction, hematopoiesis, DNA synthesis and nucleoprotein synthesis. Deficiencies in Vitamin B
12
or folic acid can lead to the inhibition of normal cell division and abnormal maturation and functioning of cells produced. These changes are most apparent in cells that undergo rapid mitosis (cell division), but all dividing cells are affected to some degree. In patients with Vitamin B
12
or folic acid deficiency, pancytopenia (diminished production of red blood cells, white blood cells and platelets) may occur. The U.S. Food and Drug Administration (FDA) recognized the description of this problem on the molecular level in its approval of B
12
for anemia.
The mechanism of action for Vitamin B
12
in IgE-mediated allergic diseases, such as allergic rhinitis and asthma, may involve the maturation of certain immune system cells including polynucleated cells, natural killer (NK) cells, and CD8+ cells. The CD8+ cell is an immune system T lymphocyte believed to “put the brakes on” the immune system, making the allergy patient less sensitive to allergens such as pollen, cats, and mold. Typically, allergic individuals have numbers of the CD8+ suppressor cells that are low relative to CD4 aggressor cells. These immune system cells may require a sustained and elevated serum Vitamin B
12
concentration to develop from an immature state to a mature state in which they can exert their down-regulatory function on the immune system. Polynucleated cells are known to have memories that last many years, a concept consistent with controlled studies demonstrating reductions in symptoms and in specific IgE levels persisting many months after parenteral Vitamin B
12
treatment.
When Vitamin B
12
is delivered parenterally, it passes into the circulation for distribution throughout the body before arriving at the liver. It is during this first pass in its native form that it is believed to exert its therapeutic effect.
Studies indicate that ingested oral cyanocobalamin is ineffective in the treatment of allergic disease, perhaps because once ingested, it goes directly to the liver where it metabolized. The ineffectiveness may also be caused by poor absorption. Gastrointestinal absorption of Vitamin B
12
depends on the presence of sufficient intrinsic factor and calcium ions. Its absorption may be hindered by the presence of large amounts of Vitamin C. Tens of millions of people have diets rich in Vitamin B
12
(from animal products or supplements) and continue to suffer from allergic rhinitis and/or asthma.
Cyanocobalamin is the most widely sold analogue of Vitamin B
12
, with other similar molecules also available. Cyanocobalamin is found in injectable and oral modes of delivery, and has the advantage over other types of B
12
of having a stable shelf life at standard temperature and pressure (STP).
The analogues of Vitamin B
12
are the only molecules used by the human body that contain cobalt. The empirical formula of cyanocobalamin is: C
63
H
88
CoN
14
O
14
P.
U.S. Pat. No. 5,135,918, which is owned by the applicant, Allergy Limited LLC, discloses a highly effective method of achieving long term relief from the symptoms of atopic allergy by repeated subcutaneous and/or intramuscular injections of B
12
over a short period of time. In practice, the treatment has comprised thirty injections of B
12
, preferably cyanocobalamin, administered twice daily over a period of fifteen days. This series of 30-injections has been successful from a point of view of efficacy in treating allergic disease, but has resulted in subjects reporting bruising and/or soreness at the local injection site. The difficulties involved in having the patient go into a medical clinic 30 times over a fifteen-day period for injections are numerous. However, providing patients with syringes for self-injection also poses problems. Once a syringe has been used it is contaminated and must be disposed of in a biohazard container or there is risk of transmitting diseases such as hepatitis or the HIV virus. Concerns have been raised about the possibility of cross-contamination of vials by lay allergy patients with minimal medical knowledge who self-inject. Both the manufacture and disposal of syringes are environmentally hazardous.
REFERENCES:
patent: 4724231 (1988-02-01), Wenig
patent: 4927850 (1990-05-01), Bayless et al.
patent: 5135918 (1992-08-01), Peraita
patent: 5508282 (1996-04-01), Tulin-Silver et al.
patent: 6066333 (2000-05-01), Willis et al.
patent: 0754450 (1997-01-01), None
patent: 5139959 (1993-06-01), None
patent: 9916417 (1999-04-01), None
Berkow et al. (eds.),The Merck Manual of Diagnosis and Therapy, 16th Edition, Merck & Co., Rahway, NJ, May, 1992, only pp. 326-327 and 2345-2348 supplied.*
Taber's Cyclopedic Medical Dictionary, 17th Edition(iIllustrated), F. A. Davis Company, Philadelphia, PA, 1989, only pp. 70-71, 1720-1721 and 1804 supplied.*
Berkow et al. (eds),The Merck Manual of Diagnosis and Therapy, 16th Edition, Merck & Co., Rahway, NJ, May, 1992, only pp. 1156-1158 supplied.*
Benet et al., “Pharmacokinetics: The Dynamics of Drug Adsorption, Distribution, and Elimination”, Chapter 1 inGoodman and Gilman's The Pharmacological Basis of Therapeutics, 8th Edition, Gilman et al.(eds), Pergamon Press, New York, NY, 1990, only pp. 3-10 supplied.
Armstrong Ernest T.
Armstrong Hepburn T.
Wise John A.
Allergy Limited
Crane L. E.
Geist Gary
Greer Burns & Crain Ltd.
LandOfFree
Cyanocobalamin (vitamin B12) treatment in allergic disease does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cyanocobalamin (vitamin B12) treatment in allergic disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cyanocobalamin (vitamin B12) treatment in allergic disease will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2478005